Chemify receives grant to develop and discover new drug candidates against tuberculosis and malaria using digital chemistry technology

Grants from the Bill & Melinda Gates Foundation will support the rapid and efficient design and synthesis of novel small molecules

GLASGOW, Scotland–(BUSINESS WIRE)–#BMGF—ChemifyA deep-tech chemical sciences company that combines chemistry, robotics and AI at scale to digitally design, discover and manufacture new molecules, today announced that it has received a grant from Bill & Melinda Gates Foundation to discover new active ingredients for the treatment of tuberculosis (TB) and malaria. By leveraging the Company's proprietary properties Chemputation Through its technology and workflows, Chemify aims to deliver unmatched results in drug development and discovery, as well as potential drug candidates, to positively impact the lives of patients worldwide.

TB is the second most common infectious disease in the world, affecting over 10 million people worldwide in 2022 and resulting in over 1 million deaths. While antibiotics can be effective in treating tuberculosis, multidrug-resistant tuberculosis (a form of tuberculosis that does not respond to first-line drugs) remains a major obstacle to the successful treatment of many patients. malaria is a life-threatening disease that remains a major burden worldwide, particularly in African regions. In 2022, there were nearly 250 million cases and over 600,000 deaths in 85 countries. Several antimalarial drugs are available to patients, but ever-increasing resistance to some therapies has prevented a complete and effective response to treatment.

Chemify will design, manufacture and discover compounds using its Chemputation technology – an automated, seamlessly controlled digital chemical stack using cheminformatics, robotics and AI to uniquely combine the digital design, planning and multiplex synthesis of novel small molecules. Potential leads are iteratively optimized in each development cycle using chemputation-driven AI. Lead compounds are then further analyzed and developed by undisclosed partners.

“TB and malaria are major global health challenges that affect millions of lives every year. “Thanks to the support of the Gates Foundation, we can leverage our digital chemistry technology to advance the discovery of novel small molecule therapeutics that can reduce the prevalence and socioeconomic burden of these two deadly diseases,” said Dr. Lee Cronin, CEO of Chemify. “Chemify’s unique chemputation technology integrates the design and synthesis of novel drug candidates at unprecedented speed. We are pleased with our progress in forming additional biotech and pharmaceutical collaborations to improve patient outcomes worldwide.”

About Chemify

Chemify is a deep-tech chemical sciences company that is redefining the research, discovery and synthesis of novel molecules for medicines and advanced materials by revolutionizing the field of chemistry through digitalization. Chemify enables digital chemistry by turning code into molecules through the process of Chemputationthat combines robotics and artificial intelligence to design and synthesize superior molecules much faster than current methods. Based in Glasgow, Scotland, Chemify was founded by CEO Professor Lee Cronin and grew out of the University of Glasgow's Digital Chemistry Laboratory to digitize chemistry on a global scale for the benefit of all humanity. Find out more at Chemify.io and keep following them X/Twitter.

Contacts

Media contact
Tim Ingersoll
[email protected]